Blue Wave Therapeutics GmbH

Blue Wave's goal is to give patients with glioblastoma a better treatment option than available therapies, as the medical need is high. The 1st product candidate (called ARAspheres) coming out of our patented platform consists of integrin-targeting alginate nanoparticles chelated to alpha-emitting radionuclide Actinium-225, and is poised to significantly improve median Overall Survival. Our business strategy is to develop ARAspheres until successful demonstration of clinical Proof of Concept to then seek an M&A exit, via a biopharma company that can progress the regulatory journey and make the product available to patients in need. Radiopharmaceuticals are becoming the new frontier in cancer treatment, attracting the interest of big pharma companies.